The global conjugate vaccines market is analyzed in detail in the latest market research report from Market Research Future (MRFR). The report studies the global conjugate vaccines market’s historical growth trajectory in order to provide pointers as to the major drivers and restraints affecting the market’s growth prospects and derive market growth markers that can indicate the market’s future growth trajectory over the forecast period from 2017 to 2023. The global conjugate vaccines market share is expected to exhibit a robust 10.5% CAGR over the forecast period, according to MRFR.
Conjugate vaccines are vaccines containing two antigens, one strong and one weak. The stronger antigen is generally made from proteins and is attached to a weaker polysaccharide antigen to form conjugate vaccines. Conjugate vaccines are used to counter diseases whose associated pathogens do not elicit a significant response from the human immune system on their own. As a result, a stronger antigen is attached to the weaker pathogen to make it more prominent and to elicit a stronger response from the immune system. The first conjugate vaccine was developed in response to the outbreak of meningitis, which still remains among the top targeted diseases in the conjugate vaccines market.
The growing government support for mass-scale vaccinations for disease eradication is likely to remain the prime driver for the global conjugate vaccines market over the forecast period. Vaccination has taken on a key role in eliminating diseases such as meningitis, which can become a serious health problem given the right conditions. The growing support for further advancement in vaccine research and development is also likely to be a major driver for the global conjugate vaccines market share over the forecast period. Considerable growth in vaccine development efforts from major market players is likely to be a major driver for the conjugate vaccines market over the forecast period.
The global polysaccharide conjugate vaccine market is segmented on the basis of type, indication, end user, and region.
On the basis of type, the global conjugate vaccine market is segmented into haemophilus B, monovalent, multivalent, and others.
On the basis of indication, the conjugate vaccines market is segmented into influenza, pneumococcal, meningococcal, and others. Influenza dominates the global conjugate vaccines market with a 35% share, however, pneumococcal and meningococcal vaccines are also likely to take up a considerable share of the global conjugate vaccines market over the forecast period.
On the basis of end users, the market is segmented into pediatrics and adults.
The global conjugate vaccines market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominates the global conjugate vaccines market due to the growing demand for wide-scale disease eradication through vaccines and the growing vaccine research environment in advanced countries such as the U.S. and Canada. The growing government support to vaccination and vaccine development in this region, along with the presence of a strong and advanced biotechnology sector in the region, is also likely to be a major driver for the conjugate vaccines market over the forecast period.
Europe follows the Americas region in terms of its share in the global conjugate vaccines market share and is likely to remain in a leading position through the forecast period due to the growing awareness about vaccines in Europe and the growing demand for developing cost-efficient, effective formulations of vaccines. The strong presence of the medical biotechnology sector in the region is also likely to be a major driver for the conjugate vaccines market in Europe.
Asia Pacific follows Europe in the global conjugate vaccines market and is likely to hold a reasonable share in the global market over the forecast period due to the growing awareness about the importance of vaccination in countries such as China and India. The growing population of this region is likely to drive the conjugate vaccines market in Asia Pacific over the forecast period.
Leading players in the global conjugate vaccine market include GSK plc, Fablife, Sanofi Pasteur SA, Sinovac Biotech Ltd., GreenSignal Bio Pharma Limited, Bavarian Nordic, Taj Pharmaceuticals Limited, IDT Biologics, Pfizer, SutroVax Inc., and Merck Co. Inc.
In March 2019, Pfizer initiated three phase III trials on its new 20-valent pneumococcal conjugate vaccine.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071